Medicine and Dentistry
Acute Coronary Syndrome
26%
Acute Heart Infarction
16%
Acute Myeloid Leukemia
18%
Advanced Cancer
25%
Adverse Event
38%
All Cause Mortality
14%
Amino Terminal Sequence
15%
Anticoagulation
14%
Aortic Stenosis
61%
Aortic Valve
14%
Aortic Valve Replacement
18%
Apoplexy
31%
Azacitidine
26%
Biliary Tract Cancer
19%
Biological Marker
28%
Bleeding
18%
Brain Natriuretic Peptide
22%
Cancer Treatment
21%
Cardiac Magnetic Resonance Imaging
17%
Cardiac Resynchronization Therapy
18%
Cardiology
55%
Cardiovascular Disease
32%
Cardiovascular Risk
28%
Cardiovascular System
37%
Chemotherapy
34%
Chronic Total Occlusion
32%
Clinical Trial
17%
Computer Assisted Tomography
23%
Congestive Heart Failure
94%
Coronary Angiography
19%
Coronary Artery Disease
24%
COVID-19
32%
Defibrillator
25%
Diagnosis
43%
Disease Exacerbation
15%
Diseases
100%
Drug Therapy
23%
Dyspnea
14%
Echocardiography
27%
Ejection Fraction
17%
Endoscopic Retrograde Cholangiopancreatography
15%
Hazard Ratio
23%
Health Care Cost
14%
Heart Amyloidosis
19%
Heart Left Ventricle Ejection Fraction
19%
Heart Surgery
15%
Hemodynamic
14%
Hospital Mortality
19%
Hypervolemia
23%
Idiopathic Pulmonary Fibrosis
19%
Immune Checkpoint Inhibitor
18%
Immunity
15%
Immunotherapy
35%
Implantable Automatic Defibrillator
30%
In Vitro
16%
Infection
33%
Inflammatory Bowel Disease
17%
Interstitial Lung Disease
17%
Liver Cirrhosis
14%
Lung Cancer
26%
Magnetic Resonance Imaging
18%
Maintenance Therapy
18%
Malignant Neoplasm
51%
Mesothelioma
20%
Meta-Analysis
52%
Mitral Insufficiency
27%
Multiple Myeloma
85%
Neoplasm
51%
Nephropathy
14%
Non Small Cell Lung Cancer
24%
Odds Ratio
26%
Oncology
28%
Outpatient
22%
Overall Survival
33%
Patient Referral
18%
Percutaneous Aortic Valve Replacement
87%
Percutaneous Coronary Intervention
34%
Personalized Medicine
18%
Pleura Mesothelioma
28%
Prevalence
46%
Primary Percutaneous Coronary Intervention
16%
Prospective Cohort Study
20%
Pulmonary Artery
16%
Pulmonary Hypertension
15%
Quality of Life
56%
Radiation Therapy
14%
Randomized Controlled Trial
17%
Reperfusion Therapy
14%
Retrospective Cohort Study
15%
Retrospective Study
22%
Revascularization
15%
Rituximab
26%
ST Segment Elevation Myocardial Infarction
33%
Symptomatic Treatment
68%
Systematic Review
61%
Targeted Therapy
19%
Thromboembolism
14%
Transplantation
24%
Tricuspid Insufficiency
17%
Valvular Heart Disease
24%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
13%
Acute Heart Infarction
7%
Acute Kidney Failure
13%
Adenocarcinoma
6%
Advanced Cancer
7%
Adverse Event
21%
Ampicillin
6%
Antibiotics
8%
Antiinfective Agent
7%
Aortic Stenosis
13%
Atorvastatin
6%
Azacitidine
6%
B Cell Maturation Antigen
7%
Biological Marker
16%
Cardiogenic Shock
7%
Cardiovascular Disease
11%
Cause of Death
9%
Cerebrovascular Accident
15%
Chemoradiation Therapy
9%
Chemotherapy
11%
Chronic Lymphatic Leukemia
13%
Chronic Thromboembolic Pulmonary Hypertension
8%
Chronic Total Occlusion
19%
Ciprofloxacin
13%
Clinical Study
9%
Cohort Study
21%
Congestive Heart Failure
35%
Coronary Artery Disease
7%
Daptomycin
6%
Darolutamide
6%
Device Infection
6%
Dexamethasone
7%
Dialysis Fluid
9%
Disease
31%
Disease Severity
8%
Durvalumab
7%
Dysglycemia
6%
Empagliflozin
10%
Enterococcus faecalis
6%
Epidermal Growth Factor Receptor
9%
Fosfomycin
13%
Glecaprevir
6%
Glutamine
6%
Heart Amyloidosis
13%
Heart Disease
7%
Heart Infarction
7%
Heart Injury
7%
Hepatitis C Virus
13%
Hospital Mortality
9%
Hypertensive Factor
7%
Hypervolemia
16%
Immune Checkpoint Inhibitor
20%
Immunotherapy
15%
Infection
15%
Inflammatory Bowel Disease
13%
Linezolid
13%
Liver Disease
7%
Lorlatinib
6%
Low Density Lipoprotein Cholesterol
13%
Malignant Neoplasm
21%
Membrane Metalloendopeptidase
7%
Meropenem
19%
Metastatic Colorectal Cancer
6%
Microdosing
6%
Multiple Myeloma
39%
Neoplasm
9%
Non Small Cell Lung Cancer
21%
Non ST Segment Elevation Myocardial Infarction
7%
Nonalcoholic Fatty Liver
13%
Opiate
11%
Osimertinib
10%
Overall Survival
8%
Pancreas Cancer
13%
Pancreatitis
8%
Peripheral Occlusive Artery Disease
7%
Peritoneal Dialysis Fluid
21%
Peritoneal Dialysis Fluid
19%
Pharmacokinetics
22%
Pibrentasvir
6%
Placebo
17%
Prevalence
33%
Programmed Death 1 Ligand 1
8%
Progression Free Survival
8%
Prospective Cohort Study
14%
Prospective Study
7%
Prosthetic Valve Dysfunction
6%
Proton Pump Inhibitor
6%
Pulmonary Hypertension
13%
Reducing Agent
6%
Remission
14%
Retrospective Study
19%
Rituximab
13%
Rosuvastatin
6%
SARS Coronavirus
7%
Selinexor
13%
Sodium Glucose Cotransporter 2 Inhibitor
7%
ST Segment Elevation Myocardial Infarction
26%
Thrombus
6%
Viral Clearance
9%
Virus RNA
13%